Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 1c
November 17, 2015 7:18 AM ESTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15).
Third Quarter 2015 and Recent Highlights
Completed enrollment in Phase II, randomized, double-blind, placebo-controlled multicenter clinical trial of NurOwn® in ALS.Successful... More